A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated

Healthy Clinical Trial

Official title:

Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Dose and Multiple Rising Oral Doses of BI 706321 in Healthy Japanese Male Subjects and Single Oral Dose of BI 706321 in Healthy Chinese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05183360
• Other study ID #: 1425-0008
• Status: Recruiting
• Phase: Phase 1
• Start date: February 3, 2022
• Est. completion date: October 21, 2025

Study information

• Verified date: April 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 1-800-243-0127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Part I: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy Japanese male subjects following oral administration of multiple rising doses.

Part II: The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 706321 in healthy Chinese male subjects following oral administration of single dose.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 21, 2025
• Est. primary completion date: October 21, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure [BP], pulse rate (PR) including body temperature, 12-lead electrocardiogram (ECG), and clinical laboratory tests at screening visit

• Part I: Japanese ethnicity, according to the following criteria:

• born in Japan, have lived outside of Japan <10 years,

• Part II: Chinese ethnicity including Taiwanese, according to the following criteria:

• have parents and grandparents who are Chinese

• Age of 20 to 45 years (inclusive) at screening visit

• Body mass index (BMI) of 18.5 to 25.0kg/m2 (inclusive) at screening visit

• Signed and dated written informed consent prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation

• Willingness to comply with contraception requirements. Subjects who are sexually active must use adequate contraception methods throughout the trial and until three months after the last administration of trial medication. Adequate methods are:

• A vasectomy performed at least 1 year prior to screening and with medical assessment of the surgical success or

• Surgical sterilisation, including bilateral tubal occlusion, hysterectomy or bilateral oophorectomy, of the subject's female partner or

• The use of condoms, if the female partner uses an adequate contraception method in addition, e.g., intrauterine device (IUD), or hormonal contraception, such as implants and injectables, combined with oral or vaginal contraceptives, that started at least 2 months prior to first drug administration, or barrier method, e.g., diaphragm with spermicide

Exclusion Criteria:

• Any finding in the medical examination (including BP, PR, body temperature or ECG) deviating from normal and assessed as clinically relevant by the investigator at screening visit

• Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 40 to 90 mmHg, or pulse rate outside the range of 40 to 99 bpm at screening visit

• Any laboratory value outside the reference range that the investigator considers to be of clinical relevance at screening visit

• Any evidence of a concomitant disease assessed as clinically relevant by the investigator

• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

• Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)

• Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders, per investigator judgement

• History of relevant orthostatic hypotension, fainting spells, or blackouts

• Further exclusion criteria apply

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• BI 706321
BI 706321
• Placebo
Placebo

Locations

Country	Name	City	State
Japan	SOUSEIKAI Sumida Hospital	Tokyo, Sumida-ku

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects with drug-related adverse events		Up to Day 27
Secondary	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-8)	part I and II	Up to Day 26
Secondary	Maximum measured concentration of the analyte in plasma (Cmax)	part I and II	Up to Day 26
Secondary	Time from dosing to maximum measured concentration of the analyte in plasma (tmax)	part I and II	Up to Day 26
Secondary	Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t (AUCt,ss)	part I	Up to Day 26
Secondary	Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t (Cmax,ss)	part I	Up to Day 26
Secondary	Minimum concentration of the analyte in plasma at steady state over a uniform dosing interval t (Cmin,ss)	part I	Up to Day 26
Secondary	Accumulation ratio based on Cmax,ss (RA,Cmax)	part I	Up to Day 26
Secondary	Accumulation ratio based on AUC0-t (RA,AUC)	part I	Up to Day 26

External Links

•   Related Info